AU2023241241A1 - Formulations comprising melphalan flufenamide and cyclodextrin - Google Patents

Formulations comprising melphalan flufenamide and cyclodextrin Download PDF

Info

Publication number
AU2023241241A1
AU2023241241A1 AU2023241241A AU2023241241A AU2023241241A1 AU 2023241241 A1 AU2023241241 A1 AU 2023241241A1 AU 2023241241 A AU2023241241 A AU 2023241241A AU 2023241241 A AU2023241241 A AU 2023241241A AU 2023241241 A1 AU2023241241 A1 AU 2023241241A1
Authority
AU
Australia
Prior art keywords
melphalan flufenamide
pharmaceutical preparation
cyclodextrin
ycd
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023241241A
Other languages
English (en)
Inventor
Kristin Hammer
Fredrik Lehmann
Rune Ringom
Peter Teodorovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncopeptides Innovation AB
Original Assignee
Oncopeptides Innovation AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Innovation AB filed Critical Oncopeptides Innovation AB
Publication of AU2023241241A1 publication Critical patent/AU2023241241A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023241241A 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin Pending AU2023241241A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
GB2204171.9 2022-03-24
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (1)

Publication Number Publication Date
AU2023241241A1 true AU2023241241A1 (en) 2024-10-31

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023241241A Pending AU2023241241A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Country Status (11)

Country Link
US (1) US20250205155A1 (https=)
EP (1) EP4499049A1 (https=)
JP (1) JP2025510725A (https=)
KR (1) KR20240161664A (https=)
CN (1) CN119053323A (https=)
AU (1) AU2023241241A1 (https=)
CA (1) CA3245985A1 (https=)
GB (1) GB202204171D0 (https=)
IL (1) IL315551A (https=)
MX (1) MX2024011654A (https=)
WO (1) WO2023180565A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
DK2701720T3 (en) 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
SMT202000058T1 (it) 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
US12152087B2 (en) 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
CA3245985A1 (en) 2023-09-28
WO2023180565A1 (en) 2023-09-28
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26
CN119053323A (zh) 2024-11-29
JP2025510725A (ja) 2025-04-15
KR20240161664A (ko) 2024-11-12
MX2024011654A (es) 2025-01-09
GB202204171D0 (en) 2022-05-11
IL315551A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
KR100941210B1 (ko) 백금 유도체를 포함하는 제약 제제
ES2767880T3 (es) Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de preparación y uso de las mismas
JP6516831B2 (ja) シクロホスファミド液状濃縮物の製剤
JP6106228B2 (ja) 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
US11224631B2 (en) Ready-to-use Carfilzomib compositions
RU2566262C2 (ru) Стабилизированная композиция вориконазола
CN107206014A (zh) 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
US20220047509A1 (en) Stabilized liquid formulation of levothyroxine
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
KR20200052326A (ko) 코판리십의 제제
US20250205155A1 (en) Formulations comprising melphalan flufenamide and cyclodextrin
EP3873529A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
CN108601730A (zh) 万古霉素的制剂
AU2013377404B2 (en) Composition of cabazitaxel and sulfobutylether beta-cyclodextrin
WO2022179490A1 (en) Pharmaceutical compositions and preparation methods thereof
EP4055005A1 (en) Liquid melphalan composition
EA052092B1 (ru) Препараты, содержащие мелфалана флуфенамид и циклодекстрин
CN111107837A (zh) 包含西普尼莫德的肠胃外制剂
AU2018328532A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
CA3117511C (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
JP2026016486A (ja) 安定なシクロデキストリン不含カルフィルゾミブ処方物
HK1233162A1 (en) Formulations of cyclophosphamide liquid concentrate
HK1259054A1 (zh) 万古霉素的制剂